Loading…
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1.5B | $331M | $242M | $480M | 13.3% | -5.2% | -34.2% |
| 2024 | $1.6B | $495M | $367M | $406M | 25.1% | -6.4% | 3.2% |
| 2023 | $1.7B | $519M | $356M | $353M | 29.6% | 49.6% | -324.8% |
| 2022 | $1.1B | $60M | $-158M | $-17M | -15.2% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 1,111.80 | 1,663.40 | 1,557.63 | 1,475.90 |
| Operating Revenue | - | 1,111.80 | 1,663.40 | 1,557.63 | 1,475.90 |
| Cost Of Revenue | - | 218.07 | 253.04 | 245.33 | 196.46 |
| Gross Profit | - | 893.73 | 1,410.37 | 1,312.30 | 1,279.44 |
| Operating Expense | - | 899.82 | 996.25 | 891.66 | 1,025.49 |
| Research And Development | - | 272.70 | 270.81 | 245.33 | 323.96 |
| Selling General And Administration | - | 590.75 | 689.75 | 645.24 | 701.52 |
| Total Expenses | - | 1,117.88 | 1,249.28 | 1,137 | 1,221.94 |
| Operating Income | - | -6.09 | 414.12 | 420.64 | 253.96 |
| Total Operating Income As Reported | - | -6.09 | 414.12 | 420.64 | 253.96 |
| EBITDA | - | 59.77 | 519.48 | 494.86 | 330.89 |
| Normalized EBITDA | - | 81.52 | 519.48 | 494.86 | 330.89 |
| EBIT | - | -18.09 | 444.55 | 466.33 | 303.73 |
| Interest Income | - | 7.63 | 30.85 | 42.45 | 45.30 |
| Interest Expense | - | 13.04 | 23.03 | 22.58 | 12.28 |
| Net Interest Income | - | -5.41 | 7.82 | 19.87 | 33.03 |
| Other Non Operating Income Expenses | - | 2.12 | -0.42 | 3.24 | 4.47 |
| Other Income Expense | - | -19.63 | -0.42 | 3.24 | 4.47 |
| Interest Income Non Operating | - | 7.63 | 30.85 | 42.45 | 45.30 |
| Interest Expense Non Operating | - | 13.04 | 23.03 | 22.58 | 12.28 |
| Net Non Operating Interest Income Expense | - | -5.41 | 7.82 | 19.87 | 33.03 |
| Pretax Income | - | -31.13 | 421.52 | 443.75 | 291.45 |
| Tax Provision | - | 2.02 | -97.64 | 71.61 | 49.79 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -4.57 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -33.15 | 519.16 | 372.14 | 241.66 |
| Net Income From Continuing And Discontinued Operation | - | -158.27 | 355.76 | 367.07 | 241.66 |
| Net Income From Continuing Operation Net Minority Interest | - | -33.15 | 519.16 | 372.14 | 241.66 |
| Net Income | - | -158.27 | 355.76 | 367.07 | 241.66 |
| Net Income Common Stockholders | - | -158.27 | 355.76 | 367.07 | 241.66 |
| Net Income Including Noncontrolling Interests | - | -158.27 | 355.76 | 367.07 | 241.66 |
| Normalized Income | - | -15.97 | 519.16 | 372.14 | 241.66 |
| Diluted NI Availto Com Stockholders | - | -158.27 | 355.76 | 367.07 | 241.66 |
| Basic Average Shares | - | 163.74 | 166.22 | 165.39 | 164.70 |
| Diluted Average Shares | - | 163.74 | 169.73 | 169.20 | 168.74 |
| Reconciled Depreciation | - | 77.86 | 74.93 | 28.53 | 27.16 |
| Reconciled Cost Of Revenue | - | 176.57 | 213.80 | 217.90 | 169.29 |
| Total Unusual Items | -1.43 | -21.75 | 0 | 0 | - |
| Total Unusual Items Excluding Goodwill | -1.43 | -21.75 | 0 | 0 | - |
| Net Income Discontinuous Operations | - | -125.12 | -163.40 | -5.07 | 0 |
| Special Income Charges | -1.43 | -21.75 | 0 | 0 | - |
| Restructuring And Mergern Acquisition | 1.43 | 21.75 | 0 | 0 | - |
| Depreciation Amortization Depletion Income Statement | - | 36.36 | 35.69 | 1.10 | 0 |
| Depreciation And Amortization In Income Statement | - | 36.36 | 35.69 | 1.10 | 0 |
| General And Administrative Expense | - | 198.54 | 199.60 | 199.02 | 221.51 |
| Other Gand A | - | 198.54 | 199.60 | 199.02 | 221.51 |
| Selling And Marketing Expense | - | 392.21 | 490.15 | 446.21 | 480.01 |
| Amortization | - | 36.36 | 35.69 | 1.10 | 0 |
| Amortization Of Intangibles Income Statement | - | 36.36 | 35.69 | 1.10 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Alkermes plcthis co. | ALKS | $7.2B | 29.92↑ premium | 3.97 | 13.3% | 20.89 |
| Henry Schein, Inc. | HSIC | $8.7B | 21.84 | 2.68 | 12.3% | 12.42 |
| Bio-Techne Corporation | TECH | $8.3B | 113.50 | 4.34 | 3.8% | 39.69 |
| Corcept Therapeutics Incorporated | CORT | $8.0B | 80.68 | 12.41 | 15.4% | 66.11 |
| Glaukos Corporation | GKOS | $7.1B | -38.08 |
| - |
| - |
| - |
| - |
| 10.89 |
| -28.6% |
| -49.02 |
| Protagonist Therapeutics, Inc. | PTGX | $6.6B | -50.79 | 10.75 | -21.2% | -41.39 |
| TG Therapeutics, Inc. | TGTX | $6.2B | 13.88 | 9.58 | 69.0% | 47.51 |
| PTC Therapeutics, Inc. | PTCT | $5.9B | 8.58 | - | -332.5% | 7.46 |
| Teleflex Incorporated | TFX | $5.8B | -6.46 | 1.87 | -29.0% | 27.09 |
| Peer Median | - | 11.23 | 9.58 | -8.7% | 19.76 | |